Iron-deficiency anemia (IDA) is an important issue. The prevalence of IDA in women of reproductive age and women in perimenopause is high and has no tendency to reduce. Pharmacoeconomic aspects and recent data on clinical efficacy of iron supplements for obstetrical gy-necological disorders are addressed. The authors review international and domestic published data on iron supplements prescribed in women with obstetrical gynecological diseases. The paper describes the results of cost-effectiveness analysis and clinical trials published earlier that compare the efficacy of the treatment with iron supplements in women who experienced IDA or gynecological disorders complicated by iron deficiency during the pregnancy. One of the bivalent iron retard preparations, Tardyferon®, is discussed. In addition, Tardyferon® is compared with similar iron supplements and Fe(III)-hydroxide-polymaltose complex. Pharmacoeconomic utility of bivalent iron preparation from the viewpoint of the patient and the doctor is validated.Keywords: pharmacoeconomic analysis, iron deficiency, iron-deficiency anemia, pregnancy, iron supplements, bivalent iron.For citation: Dobrokhotova Yu.E., Markova E.A. Peroral retard iron preparation for iron-deficiency anemia: case study and pharmacoecono-mic analysis. Russian Journal of Woman and Child Health. 2020;3(2):88–94. DOI: 10.32364/2618-8430-2020-3-2-88-94.